Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
5.48 EUR
12.84 B EUR
77.15 B EUR
2.40 B
About Johnson & Johnson
Sector
CEO
Joaquin Duato
Headquarters
New Brunswick
Website
Founded
1887
FIGI
BBG000DS2QQ5
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Gamma peak on 145 indicating up direction Gamma peak on 145 indicating up direction , its demand and support area with MACD Histogram Divergence seen its supposed to go toward 148 in case 144/143 will hold
Technical Analysis of Johnson & Johnson Stock (JNJ)This chart for JNJ illustrates a technical setup within a descending channel. Key Fibonacci retracement levels (38.2%, 50%, and 61.8%) are highlighted, indicating potential zones of support and resistance. The analysis suggests a three-part buying strategy: an initial purchase at the current market
JNJ major support...must hold, buying a few shares here
the inverse head and shoulder failed, NYSE:JNJ is now close to the bottom of this multi-year flag...
it must hold or a bigger flush may occur, given the stability of the company, I am leaning towards a bounce and buying a few shares for the long term
no options till price close above the 9/21
Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight.
$JNJ Call verticalNYSE:JNJ has been declining for some time. Currently the bullish divergence is everywhere. The price is also outside the BB band. I think there is a very good change for the price to move up in the coming days.
I bought Jan. 2025 $150/$155 call vertical for $2.33
I will double my money if the stoc
JNJ Long consolidation..potential breakoutNYSE:JNJ has been consolidating for over 2 years on this range now:
* monthly bull flag
* forming the right shoulder of an IHS on weekly chart (can even see it on the monthly)
* healthcare sector oversold, so can see a bounce
a bounce could push JNJ to test the upper trendline at 165-166.
The IHS
$150 support for JNJ?$150 was a popular area from April to July. Once it finally broke through, it went to its high for the year of $168. Even after a good earning report, JNJ has been on the decline since. It hopefully found support at $150. It stayed in the support range for two days and immediately had the bullis
JNJThe JNJ stock is in a strong downtrend and has bounced back four times from it. We expect the stock to make a new low below $140, with a stop loss if it breaks above the last high at $167.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where JNJ is featured.
Frequently Asked Questions
The current price of JNJ is 139.02 EUR — it has decreased by −0.16% in the past 24 hours. Watch JOHNSON + JOHNSON DL 1 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange JOHNSON + JOHNSON DL 1 stocks are traded under the ticker JNJ.
JNJ stock has risen by 1.47% compared to the previous week, the month change is a −6.36% fall, over the last year JOHNSON + JOHNSON DL 1 has showed a −1.33% decrease.
We've gathered analysts' opinions on JOHNSON + JOHNSON DL 1 future price: according to them, JNJ price has a max estimate of 204.73 EUR and a min estimate of 151.40 EUR. Watch JNJ chart and read a more detailed JOHNSON + JOHNSON DL 1 stock forecast: see what analysts think of JOHNSON + JOHNSON DL 1 and suggest that you do with its stocks.
JNJ stock is 1.17% volatile and has beta coefficient of 0.00. Track JOHNSON + JOHNSON DL 1 stock price on the chart and check out the list of the most volatile stocks — is JOHNSON + JOHNSON DL 1 there?
Today JOHNSON + JOHNSON DL 1 has the market capitalization of 337.61 B, it has increased by 1.25% over the last week.
Yes, you can track JOHNSON + JOHNSON DL 1 financials in yearly and quarterly reports right on TradingView.
JOHNSON + JOHNSON DL 1 is going to release the next earnings report on Jan 22, 2025. Keep track of upcoming events with our Earnings Calendar.
JNJ earnings for the last quarter are 2.17 EUR per share, whereas the estimation was 1.98 EUR resulting in a 9.68% surprise. The estimated earnings for the next quarter are 1.94 EUR per share. See more details about JOHNSON + JOHNSON DL 1 earnings.
JOHNSON + JOHNSON DL 1 revenue for the last quarter amounts to 20.18 B EUR, despite the estimated figure of 19.91 B EUR. In the next quarter, revenue is expected to reach 21.60 B EUR.
JNJ net income for the last quarter is 2.42 B EUR, while the quarter before that showed 4.37 B EUR of net income which accounts for −44.69% change. Track more JOHNSON + JOHNSON DL 1 financial stats to get the full picture.
Yes, JNJ dividends are paid quarterly. The last dividend per share was 1.18 EUR. As of today, Dividend Yield (TTM)% is 3.37%. Tracking JOHNSON + JOHNSON DL 1 dividends might help you take more informed decisions.
JOHNSON + JOHNSON DL 1 dividend yield was 3.00% in 2023, and payout ratio reached 84.93%. The year before the numbers were 2.52% and 66.07% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 26, 2024, the company has 131.90 K employees. See our rating of the largest employees — is JOHNSON + JOHNSON DL 1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JOHNSON + JOHNSON DL 1 EBITDA is 25.92 B EUR, and current EBITDA margin is 34.82%. See more stats in JOHNSON + JOHNSON DL 1 financial statements.
Like other stocks, JNJ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JOHNSON + JOHNSON DL 1 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JOHNSON + JOHNSON DL 1 technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JOHNSON + JOHNSON DL 1 stock shows the sell signal. See more of JOHNSON + JOHNSON DL 1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.